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It is a longstanding puzzle why non-coding variants in the complement factor H (CFH) gene are more strongly
associatedwith age-relatedmacular degeneration (AMD) than functional coding variants that directly influence
the alternative complement pathway. The situation is complicated by tight genetic associations across the
region, including the adjacentCFH-relatedgenesCFHR3 andCFHR1, whichmay themselves influence the alter-
nativecomplementpathwayandarecontainedwithinacommondeletion (CNP147)which isassociatedwithpro-
tection against AMD. It is unclearwhether this association ismediated through a protective effect of lowplasma
CFHR1 concentrations, high plasma CFH or both. We examined the triangular relationships of CFH/CFHR3/
CFHR1 genotype, plasma CFH or CFHR1 concentrations and AMD susceptibility in combined case–control
(1256 cases, 1020 controls) and cross-sectional population (n5 1004) studies and carried out genome-wide as-
sociation studies of plasma CFH and CFHR1 concentrations. A non-coding CFH SNP (rs6677604) and the
CNP147deletionwerestronglycorrelatedbothwitheachotherandwithplasmaCFHandCFHR1concentrations.
The plasmaCFH-raising rs6677604 allele and raised plasmaCFH concentrationwere each associatedwith AMD
protection. In contrast, the protective association of the CNP147 deletion with AMD was not mediated by low
plasma CFHR1, since AMD-free controls showed increased plasma CFHR1 compared with cases, but it may
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bemediated by the association of CNP147with raised plasmaCFH concentration. The results aremost consist-
ent with a regulatory locus within a 32 kb region of theCFH gene, with amajor effect on plasma CFH concentra-
tion and AMD susceptibility.
INTRODUCTION
Age-related macular degeneration (AMD) is the major cause of
registered blindness in westernized countries, with 15–30
million people affected globally (1,2). There is currently no
established means of preventing disease progression, although
ocular injection of angiogenesis inhibitors in late neovascular
AMD can halt or even reverse visual loss (3). Prospective
studies show that progression to advanced stages of AMD is
strongly predicted by risk genotypes in two genomic regions:
complement factor H (CFH, OMIM #134370) and ARMS2/
HTRA1 (OMIM #611313) (4,5). The function of the ARMS2/
HTRA1 locus is unclear (6), but CFH is a strong suppressor of
complement activation, acting at the level of C3b (7,8). CFH
inhibits alternative pathway activation both in plasma and on
cell surfaces by promoting C3b proteolysis and either preventing
the formation or enhancing the dissociation of C3 convertases.
This pathway is strongly implicated in AMD risk (9), since
several components are either present in diseased tissues, such
as the characteristic extracellular drusen deposits (CFH, C3b/
iC3b, BF, C5b-9), or they are genetically associated with
disease risk (C3, C2/BF, CFH, CFHR1, CFHR3, CFI) (10,11).
Mutations in CFH are also implicated in the renal disorders
type II membranoproliferative glomerulonephritis and atypical
haemolytic–uraemic syndrome (aHUS) (8), and one rare
variant is implicated in causing both AMD and aHUS (12).
The CFH gene encodes two protein products, CFH and factor
H-like 1 (FHL-1) by alternative splicing. The 7 short consensus
repeats (SCRs) of FHL-1 are identical to the N-terminal part of
CFH, which has 20 SCRs. FHL-1 also differs from CFH
because of an additional four amino acids at its C-terminus
(SCR7) and the availability of an RGD motif in SCR4 associated
with adhesive activity (13). The molar concentration of FHL-1 in
plasma is only 10–30% of plasma CFH levels (14).
The structurally similar CFH-related proteins CFHR1 and
CFHR3 are also less abundant than CFH in plasma and are
encoded by genes immediately adjacent to CFH within the
Regulator of Complement Activation (RCA) gene cluster in
chromosomal region 1q31.3. CFHR1 and CFHR3 have also
been proposed to influence both aHUS and AMD susceptibility
via effects on complement activity (15,16). CFHR1 inhibits C5
convertase activity and terminal membrane attack complex
(MAC) formation, whereas CFHR3 inhibits C3 convertase ac-
tivity in vitro (16,17). CFHR1, CFHR3 and CFH show consider-
able sequence homology in their C-terminal SCR modules,
which have been proposed to compete for binding to C3b and
heparin, consistent with a regulatory role (16,17). Homozygosity
for a common 86 kbCFHR3/CFHR1 (CNP147) deletion, which
has an allele frequency of 0.2–0.3 in Western populations, is
associated with increased risk of aHUS, suggesting that one or
both proteins act together to suppress MAC formation and in-
flammation (16). But, in AMD, the situation is reversed, since
CNP147 homozygosity is associated with protection against
macular degeneration (18), which has been explained by the
beneficial effects of enhanced opsonin (iC3b, C5a) formation,
promoting phagocytosis of opsonized particles in AMD due to
the reduced inhibition of the C5 convertase (15,17,19).
However, interpreting these genetic associations is complicated
by the presence of strong linkage disequilibrium (LD) across the
region. Hughes et al. (18) initially proposed that the CNP147 de-
letion acts independently of non-synonymous coding variants in
CFH, such as Y402H, which affect CFH function (20–22). Sub-
sequent analyses, however, showed that the strongest associa-
tions with AMD across the CFH-CFHR3-CFHR1 region were
independent of the CNP147 deletion (23,24) and resulted from
non-coding or synonymous variants lying within a small 32 kb
region in the CFH gene between rs203687 in intron 9 and
rs1329427 in intron 15 (25).
In order to try and resolve these issues, we measured the tri-
angular relationships between CFH-CFHR3-CFHR1 geno-
types, plasma concentrations of CFHR1 and CFH plus FHL-1
(hereafter referred to as ‘CFH’) and AMD susceptibility, using
both cross-sectional population cohort (n ¼ 1004) and AMD
case–control series (1256 cases, 1020 controls) (see Supple-
mentary Material, Table S1 and Fig. S1). We identified a locus
within the CFH gene with a substantial effect on both plasma
CFH and CFHR1 concentrations, consistent with the stronger as-
sociation of AMD with non-coding rather than non-synonymous
coding CFH SNPs. We also found that raised plasma CFH con-
centration and the presence of a plasma CFH-raising allele at
CFH SNP rs6677604 were each associated with AMD protec-
tion. On the other hand, whereas the CNP147 deletion was asso-
ciated with AMD protection, measured plasma CFHR1 was
unexpectedly lower in AMD cases than controls, excluding the
possibility that disease protection by CNP147 is mediated by
reduced plasma CFHR1. Instead, the association of CNP147
with raised plasma CFH may be the major protective influence,
whereas the low CFHR1 concentration in AMD cases appears to
be due to confounding influences, such as the effect of disease
per se.
RESULTS
Genotypic effects on plasma CFH and CFHR1
concentrations
Plasma CFH was normally distributed with a 3-fold range (218–
654 mg/ml) and a mean of 400+ 62 (SD) mg/ml in a Croatian
(Vis) cross-sectional population sample (n ¼ 1004) (Supple-
mentary Material, Fig. S2 and Table S2). Plasma CFHR1 con-
centrations, expressed as a fraction of the reference samples
used in the enzyme-linked immunosorbent assay (ELISA),
were measured in the same samples and were also normally dis-
tributed, with a mean of 0.93+ 0.20 (SD) standardized units and
a range of 0.19–1.55 (Supplementary Material, Fig. S2 and
Table S2). To exclude possible cross-reactivity between the
4858 Human Molecular Genetics, 2013, Vol. 22, No. 23







two assays, we examined the correlation between plasma CFH
and CFHR1 concentrations, using the residuals from linear
regressions of each analyte on age, sex and genotype. Adjust-
ment for age, sex and genotype is appropriate because to
detect cross-reactivity we want to eliminate associations
between CFH and CFHR1 concentrations that are explained by
covariates. We evaluated the posterior distribution of the re-
sidual correlation in the Bayesian linear regression model used
for the instrumental variable analysis (see below): this yields
point and interval estimates (posterior mean and 95% credible
interval) that allow for missing genotypes and phase uncertainty.
The correlations between residuals of plasma CFH and CFHR1
concentrations were 0.01 (95% CI20.02 to 0.04) in the Scottish
AMD (SAMD) sample and20.05 (95% CI20.11 to 0.00) in the
Croatian samples, clearly showing that any cross-reactivity
between the two assays is minimal.
We took advantage of the genetic relationships within the Cro-
atian isolate population to estimate the heritability of plasma
CFH and CFHR1 concentrations. Narrow-sense heritability,
which is the proportion of the total phenotypic variance due to
additive genetic variance, was estimated to be 0.46+ 0.13
(SEM) for plasma CFH and 0.69+ 0.12 (SEM) for plasma
CFHR1 concentration in the Croatian population, consistent
with a substantial heritable component for both biomarkers.
In order to identify genetic variants influencing plasma CFH
concentration, a genome-wide association study (GWAS) was
carried out in the Croatian population cohort (n ¼ 1004), as
described previously (26) using 317 503 SNPs (Supplementary
Material, Fig. S3). The SNP most strongly associated with
plasma CFH concentration was rs6677604 in CFH intron 11
(Fig. 1), with each minor (A) allele increasing CFH concentra-
tion by 25.6 mg/ml (SEM 1.6) (P ¼ 1.1 × 10261) (Fig. 2A and
Supplementary Material, Table S3). This SNP explained 26%
of the measured variance in plasma CFH concentration (57%
of additive genetic variance), adjusted for covariates age, sex
and BMI. The result was replicated in 500 unrelated individuals
from a Dutch (Rucphen) cross-sectional population cohort (Sup-
plementary Material, Tables S1 and S2) (27), in which
rs6677604 was again the most strongly associated SNP [b ¼
41.5 mg/ml (SEM 3.9), P ¼ 6 × 10224], using the same covari-
ates (Supplementary Material, Table S4).
A GWAS was also carried out to identify genetic variants in-
fluencing plasma CFHR1 concentration in the same Croatian
population cohort. The strongest genotypic association of
plasma CFHR1 was again found for CFH SNP rs6677604, at
which the minor (A) allele decreased plasma CFHR1 concentra-
tion [b ¼ 20.23+ 0.01 (SEM), P ¼ 1.31 × 10276], and with
the CNP147 deletion, which was associated with reduced
plasma CFHR1 [b ¼ 20.22+ 0.01 (SEM), P ¼ 3.98 ×
10271] (Fig. 1, Supplementary Material, Fig. S3 and
Table S3). The rs6677604 minor (A) allele is highly correlated
with the CNP147 deletion (r2 ¼ 0.84) (Supplementary Material,
Table S5) and this locus explained 40% of the measured variance
in plasma CFHR1 concentration (58% of additive genetic vari-
ance), adjusted for age, sex and BMI in the regression model.
The plasma concentration of CFHR1 was inversely correlated
with the CNP147 deletion genotype [r ¼ 20.62, P ¼ 4.3 ×
10242 (Croatians) and r ¼ 20.43, P ¼ 1.2 × 10223 (SAMD)]
(Fig. 2B). Analysis of LD in the unrelated individuals from the
Croatian data set showed that the minor allele (A) of CFH
SNP rs6677604 was only weakly correlated with the minor
alleles of two non-synonymous SNPs that have previously
been associated with AMD risk, in exon 2 [rs800292 (I62V),
T-allele, r2 ¼ 0.04] (28) and exon 9 [rs1061170 (Y402H)
C-allele, r2 ¼ 0.16] (20–22).
Figure 1. Results of GWAS of plasma CFH and CFHR1 in a normal population
cohort. Variants in the CFH gene and the CNP147 deletion show the strongest
genetic associations with both plasma CFH and plasma CFHR1 concentrations.
(A) Manhattan plot summarizing GWAS results of plasma CFH in a Croatian
cross-sectional population cohort (n ¼ 1004) showing transformed (2log10)
P-values for all SNPs used in the study. A similar plot for plasma CFHR1 is
shown in Supplementary Material, Figure S3. (B) GWAS results using a full
mixed model showing chromosomal region 1q32 in more detail: the locations
and genetic association P-values for 27 SNPs in the CFH to CFHR5 genomic
region are shown. (C) The corresponding results for the plasma CFHR1 GWAS
(n ¼ 1004). (D) Genomic annotations showing the boundaries of the CFHR3/
CFHR1 (CNP147) deletion (dotted vertical lines), direction of transcription
(arrows) and genomic location of exons (to scale, vertical lines within the genes).
Human Molecular Genetics, 2013, Vol. 22, No. 23 4859







In order to examine the effects of additional variants in this
region, we repeated the GWAS for both plasma CFH and
CFHR1 on 1000 Genomes Project imputed data (http://www.
1000genomes.org/ last accessed July 2013) after adjusting for
age, sex, age-by-sex and body mass index and using a score
test for association (mmscore) in related individuals, as imple-
mented in the GenABEL suite (29,30). Variants which were
poorly imputed (Rsq ≤ 0.4) were filtered out. The analysis
focused on a 500 kb window encompassing the CFH- and
CFH-related genes (Fig. 3). Furthermore, we assessed the LD
between the imputed top SNP (rs16840522) and our top SNP
(rs6677604), using SNAP (http://www.broadinstitute.org/mpg/
snap last accessed July 2013). These two SNPs are 24 kb apart,
with an r2 ¼ 0.98 and D′ ¼ 1.00, showing that they are in very
high LD. Both SNPs lie within the 32 kb region ofCFH referred
to above. We repeated the plasma CFH and CFHR1 association
analysis adjusting for our original top SNP (rs6677604). The
peaks for all the SNPs in LD with rs16840522 disappeared, sug-
gesting that the same signal had been picked up in our original
GWAS as with the imputed GWAS (Supplementary Material,
Fig. S4).
Association between plasma CFH and CFHR1
concentrations and AMD
We next examined the relationships between plasma CFH or
CFHR1 and disease. The odds ratios for the effect of plasma
CFH and CFHR1 concentrations on AMD risk were computed
by logistic regression using data from a previously described
SAMD case–control series (31) including 382 cases and 201
controls (Supplementary Material, Table S1 and Fig. S1). The
mean unadjusted plasma CFH concentration was 15.7mg/ml
(0.27 standard deviations) lower in cases [412.6+ 2.98 (SEM)
mg/ml] than controls [428.3+ 3.66 (SEM)mg/ml] (P ¼ 0.001)
(Fig. 4, Supplementary Material, Table S2). This difference
remained significant after adjusting for age and sex (P ¼ 0.002).
The odds ratio for a plasma CFH increase of 1 standard deviation
on AMD risk was estimated to be 0.52 (95% CI 0.37–0.70).
The mean unadjusted plasma CFHR1 concentration was also
lower (by 0.28 standard deviations) in SAMD cases [0.94+
0.009 (SEM) standardized units] compared with controls
[0.99+ 0.016 (SEM) standardized units] (P ¼ 0.001). The dif-
ference remained significant after adjusting for age and sex
(P ¼ 0.002) (Fig. 4, Supplementary Material, Table S2). This
result was surprising since previous genotyping studies (18) sug-
gested a protective effect of the CNP147 deletion on AMD risk,
and the deletion allele was associated with decreased plasma
CFHR1 concentration (Fig. 2B). AMD cases were, therefore,
expected to show higher plasma CFHR1 than controls. Instead,
increased plasma CFHR1 was protective for AMD, after adjust-
ing for sex, age and plasma CFH concentration [odds ratio for the
effect of a 1 standard deviation increase in plasma CFHR1 on
AMD risk was 0.72 (95% CI 0.59–0.87; P ¼ 0.001)]. The pro-
tective association between the CNP147 deletion and AMD
risk is, therefore, not mediated by its effect on lowering
plasma CFHR1 concentration.
In order to exclude the possibility that the plasma CFH or
CFHR1 differences between cases and controls are due to the
age-dependence of plasma CFH (and potentially CFHR1) con-
centrations or to smoking status (32), we repeated the analyses
after additionally adjusting for age, sex and smoking status,
but did not find substantial differences.
The OX23 monoclonal antibody (33) used in the CFH assay
does not cross-react with CFH-related proteins (CFHR1-5) but
Figure2.Effects ofCFHSNP rs6677604 and the CNP147 deletion on plasma CFH and CFHR1 concentrations, respectively. (A) Means and 95% confidence intervals
of plasma CFH in the Croatian population cohort showing the association with rs6677604 SNP genotypes (GG, GA, AA). The minor allele (A) is associated with an
increase in plasma CFH under an additive model [r ¼ 0.52, P ¼ 2.9 × 10233 (two-tailed, n ¼ 451)]. Error bars are 95% confidence intervals of the mean (black
squares). n is the number of unrelated individuals in each group. (B) The CNP147 (CFHR3/CFHR1) deletion (D) genotype and plasma CFHR1 concentrations are
correlated in the Croatian cross-sectional population cohort. As the CNP147 copy number changes from 0 to 2, plasma CFHR1 concentrations are reduced accordingly
[r ¼ 20.62,P ¼ 4.3 × 10242 (two-tailed, n ¼ 505)]. Error bars are 95% confidence intervals of the mean (black squares). A similar result was obtained in the SAMD
series (see text).
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Figure 3. GWAS of plasma CFH and CFHR1 concentrations in the Croatian cohort (n ¼ 1004), including both genotyped and imputed SNPs. Manhattan plots
showing GWAS results for plasma CFH (A) and CFHR1 (B) using 1000 Genomes Project imputed data, in which the circles show the statistical strength of the
association (2log10 P-value), coloured according to the pair-wise correlations (r
2) between surrounding markers and the most strongly associated variant
(imputed SNP rs16840522). Variants that were poorly imputed (imputation Rsq ≤ 0.4) were filtered out and the results are shown for a 500 kb window encompassing
theCFH andCFHR1-5genes. The right-handy-axis and purple line show recombination rates across the region, whereas the x-axis shows the position on chromosome
1 and genomic annotations showing the boundaries of theCFHR3/CFHR1 (CNP147) deletion (dotted vertical lines), direction of transcription (arrows) and genomic
location of exons (to scale, vertical lines within the genes).
Human Molecular Genetics, 2013, Vol. 22, No. 23 4861







does detect the CFH isoform, FHL-1. In order to investigate
whether plasma FHL-1 also differs between AMD cases and
controls, we carried out western blot analysis on plasma from
five individuals with high plasma CFH concentrations and five
individuals with low plasma CFH concentrations as previously
determined by ELISA. In western blots, the OX23 antibody
did not perform well, so the monoclonal murine anti-human
CFH antibody (Quidel, clone 90X) was used, which binds specif-
ically to SCR-1 on both CFH and factor H-like proteins (34)
(Supplementary Material, Fig. S5). The blot images were ana-
lysed by densitometry, which showed that, even in such a
small sample, differences could be seen in plasma CFH, but
FHL-1 concentrations were comparatively small (molar concen-
tration 1.8–8.1% of the CFH peak) and did not differ significant-
ly between high and low CFH samples. The major association
signal appeared, therefore, to be due to CFH rather than FHL-1.
Genetic effects at the CFH-CFHR1-CFHR3
loci on AMD susceptibility
For the analysis of genetic effects on AMD risk, two case–
control series were combined: the SAMD case–control series
(31), which included a subset of 242 advanced AMD cases (atro-
phic or neovascular type) and 201 controls in whom both plasma
CFH and CFHR1 had been measured, and an English AMD
(EAMD) case–control series with 874 advanced AMD cases
and 418 controls (31) (Supplementary Material, Table S1 and
Fig. S1). The analysis focused on 12 genetic variants—11
SNPs and the CNP147 deletion (Fig. 5). These SNPs were
chosen because they fulfilled one or more of the following cri-
teria: (i) they encoded non-synonymous and potentially func-
tional coding changes in CFH (rs1061170, rs800292) or
CFHR1 (rs388862); (ii) they were strongly associated with
plasma CFH or CFHR1 concentration in the GWAS, including
non-coding SNPs rs2019727, rs1048663, rs6677604,
rs1329428, rs412852, rs11582939 and the CNP147 deletion
(Fig. 1); (iii) they were the SNPs most strongly associated with
AMD in other studies (rs2274700, rs1410996) (23,24).
The association of CFH/CFHR3/CFHR1 SNPs with AMD
was first examined by univariate logistic regression analysis,
adjusting for age and sex. The magnitude and the direction of
the effect of the 12 variants on AMD risk are shown in
Figure 5, where they are also compared with their effects on
plasma CFH or CFHR1, as determined in the SAMD case–
control series and the Croatian population cohort. BMI was not
measured in the SAMD or EAMD studies and so was not used
as a covariate in this analysis. The results showed, first, that for
many but not all SNPs, the genotypic effects on AMD risk
were consistent with their effects on plasma CFH, in which
increased plasma CFH was protective against AMD (Supple-
mentary Material, Fig. S6).
Two additional observations were made. First, the CNP147
deletion was associated both with reduced plasma CFHR1
(P ¼ 1.2 × 10223) and with increased plasma CFH concentra-
tions (P ¼ 1.3 × 1026) after adjusting for sex and age. This sug-
gests an alternative mechanism whereby the CNP147 deletion
could be associated with protection from AMD—through the as-
sociation of CNP147 with raised plasma CFH, which was con-
sistently protective against AMD, based both on genotype
predictions and direct measurements (Fig. 4). Second, for
those five CFH SNPs located within the 32 kb region reported
to show the strongest association with AMD (25) (highlighted
in orange in Fig. 5), the minor alleles were each associated
with increased plasma CFH and lower AMD risk. The direction
of SNP effects on plasma CFH is shown for their minor alleles,
and the same alleles are consistently associated with opposite
effects on plasma CFHR1 concentration (Fig. 5A). In contrast,
CFH SNPs that alter the sequence and potentially the function
of the protein [rs1061170 encoding Y402H (20–22,35,36) and
rs800292 encoding I62V (28,35,37)] have effects on plasma
CFH that appear uncorrelated with their effects on AMD risk
(Fig. 5). For example, the above two non-synonymous CFH
SNPs are associated with either no effect or a marginally lower
Figure4.Comparison of plasma CFH and CFHR1 concentrations in the SAMD series. Unadjusted plasma CFH (A) and CFHR1 (B) concentrations in 382 AMD cases
and 201 disease-free controls. The mean and 95% confidence intervals are shown. The differences in mean value were statistically significant for plasma CFH and
CFHR1 after adjusting for age, sex and smoking status. ∗∗∗P , 0.001, using a t-test (two-tailed).
4862 Human Molecular Genetics, 2013, Vol. 22, No. 23







plasma CFH, whereas both show a substantially increased AMD
risk. Similarly, these SNP alleles are associated with either
raised or lowered plasma CFHR1 and yet both are associated
with a substantially increased AMD risk. This applies also to
the minor allotype of complex SNP rs388862 (see Materials
and Methods), which alters the protein sequence of CFHR1
(38) but has no significant effect on either plasma CFH or
CFHR1 and yet is associated with a substantially lower AMD
risk [Fig. 5 and (39)]. We, therefore, adjusted for these three non-
synonymous SNPs as additional covariates in the regression
model and re-examined the univariate effects of the remaining
nine loci on AMD risk (Fig. 5B, right-hand caption). The result-
ing genotype-disease associations remained consistent with the
measured plasma CFH concentrations, suggesting that, after
accounting for functional SNP effects, high plasma CFH had a
protective effect on AMD susceptibility, although an effect of
low plasma CFHR1 could not be excluded. A multivariate
analysis was, therefore, carried out to examine their relative con-
tributions in more detail.
Inference of causal effects due to plasma CFH
and CFHR1 on AMD susceptibility
The results discussed above all involved combining different
study data sets, all of which (SAMD, EAMD, Croatian) were
genotyped across the RCA locus but only some of which had
measurements of plasma CFH or CFHR1 (SAMD, Croatian).
The resulting triangular associations (Supplementary Material,
Fig. S6) were examined in a multivariate analysis in order to in-
dicate causal effects or otherwise of plasma CFH and CFHR1
concentration on AMD susceptibility. This was done by means
of an instrumental variable (‘Mendelian randomization’) ana-
lysis (see Materials and Methods and Supplementary Material,
for further description). We used a Bayesian model since this
Figure 5. Univariate analysis predicts that SNPs located within a 32 kb region of the CFH gene have strong (but opposite) effects on plasma CFH and CFHR1 con-
centration. (A) Results of univariate logistic regression analysis showing the direction and magnitude of minor allele effect sizes of 12CFH/CFHR1 genetic variants
influencing plasmaCFH, plasma CFHR1and AMD risk. Univariate linear regression coefficients are shown for the effects of minor allele genotypeon plasmaCFH and
CFHR1, adjusted for age and sex, based on a combined analysis of SAMD control and Croatian samples. SNPs lying within a 32 kb region ofCFH proposed by Siva-
kumaranet al. (25) to influenceAMDrisk are highlighted in orange. (B) Univariate logistic regression coefficients for the effects of genotypeon AMD risk, adjusted for
age, sex and cohort (left panel) or age, sex, cohort and three non-synonymous SNPs in CFH and CFHR1 (right panel), based on the combined analysis of SAMD and
EAMD case–control series.
Human Molecular Genetics, 2013, Vol. 22, No. 23 4863







can readily deal with missing data and multiple data sets. The
analysis combined genotypic, biomarker (plasma CFH/
CFHR1) and AMD data from the SAMD, EAMD and Croatian
populations in a single model, bringing together the relationships
between each point in the triangle, as discussed above.
The results of the analysis indicated a causal protective effect
of plasma CFH on AMD risk, with an odds ratio for an increase of
1 standard deviation in plasma CFH concentration of 0.52 (95%
CI 0.37–0.70), based on the posterior distribution of the log odds
ratio. The corresponding causal odds ratio for plasma CFHR1
concentration on AMD risk was not significantly different
from the null value of 1, with an odds ratio of 1.32 and 95% CI
value of 0.88–2.08. Functional SNPs in CFH or CFHR1 are
likely to have effects on AMD that are not mediated by plasma
CFH or CFHR1 (pleiotropic effects) and so were included as
covariates in the regression model. The direct effects of the
two non-synonymous CFH SNPs on AMD risk were either pro-
tective (rs800292 minor allele) [(odds ratio for one extra copy of
the minor allele was 0.47 (95% CI 0.36–0.62)] or increased risk
[odds ratio for one extra copy of the minor allele was 1.69 (95%
CI 1.33–2.13)]. There was no evidence of a direct effect of the
CFHR1 nsSNP rs388862 on AMD risk (odds ratio 0.96, 95%
CI 0.69–1.34). These results, first, emphasize the importance
of accounting for the pleiotropic effects of the non-synonymous
CFH SNPs on AMD risk in the model. Second, the results were
consistent with a causal effect of lower plasma CFH (and only a
possible effect of raised plasma CFHR1) on AMD risk.
DISCUSSION
We show that variation in the CFH gene, at sites other than the
two potentially functional nsSNPs, I62V and Y402H, is asso-
ciated with large effects on plasma CFH concentration. The
most strongly associated SNP is rs6677604 in CFH intron 11,
which accounts for about half of the genetic variance in
plasma CFH in a univariate analysis. Our results are consistent
with a causal regulatory locus within a 32 kb region of the
CFH gene, which includes rs6677604 (25). The nature of this
locus remains unknown, since no candidate eQTL maps to the
region of rs6677604 and we were unable to identify enhancer ac-
tivity using luciferase reporter assays, although the region
remains to be comprehensively screened. No locus outside the
RCA gene cluster in chromosomal region 1q32 was evident in
the GWAS of plasma CFH or of CFHR1 (Supplementary Mater-
ial, Fig. S3).
Plasma CFH concentration varied by a factor of 3 in our popu-
lation sample and showed high heritability, as reported in other
populations (32). The plasma CFH concentration measured by
our ELISA assay included both CFH and its alternatively
spliced isoform FHL-1; so, we cannot discriminate between
these isoforms, although we confirmed that CFH is expressed
at over 10-fold higher molar concentration in plasma compared
with FHL-1 [Supplementary Material, Fig. S5 and (40)]; so,
FHL-1 is unlikely to influence the reported genetic associations
substantially. Also, CFH and CFHR1 concentrations in the Cro-
atian population cohort were found to be inversely correlated,
with a Pearson correlation coefficient of 20.34 (95% CI
20.40 to 20.28) (P-value , 2.2 × 10216) after adjusting for
covariates, suggesting that although the ELISAs are measuring
different proteins, loci influencing their expression levels are
in some degree of LD, which spans most of the RCA region
(see Supplementary Material, Table S5).
Could the proposed locus influencing plasma CFH explain the
effect of the CNP147 deletion on AMD risk as a result of LD
across the region? The CNP147 deletion was in LD with
CFH-raising alleles at rs6677604 (r2 ¼ 0.84) and rs2274700
(r2 ¼ 0.33), a synonymous coding SNP (A473A) in exon 10 of
CFH (24), both of which are located within a 32 kb region of
the CFH gene that shows the strongest association with AMD
(23–25). Fritsche et al. (16) found evidence for the conditional
independence of the CNP147 deletion from CFH SNPs
rs2274700 (Ala473Ala) and rs1061170 (Y402H) and their
effects on AMD risk. In contrast, Raychaudhuri et al. (41)
used a larger panel of CFH SNPs and found that the protective
effect of CNP147 was not independent of CFH haplotypes.
We concur with this result, since we found strong LD between
rs6677604 and CNP147, suggesting that their effects are likely
to be hard to separate genetically.
As the CFH-raising minor (A) allele atCFHSNP rs6677604 is
strongly correlated with the CNP147 deletion, the association of
this deletion with lower AMD risk is compatible with a protect-
ive effect of high plasma CFH concentration or of low plasma
CFHR1 concentration (or both). It has been suggested that low
CFHR1 concentration (predicted by genotype but not previously
measured) protects against AMD by reduced competitive inhib-
ition of CFH binding to tissue surfaces, leading to greater inhib-
ition of the C3 convertase by CFH and consequently enhanced
protection against inflammation (16). Alternatively, the genetic-
ally predicted reduction in plasma CFHR1 may increase C5 con-
vertase and MAC formation, the former leading to enhanced
opsonization of particles, which may be advantageous in AMD
(but not aHUS). A further possibility is that the two proteins,
CFH and CFHR1, act sequentially on the alternative pathway
C3 and C5 convertases, consistent with the observed competi-
tion for C3b binding and their presence together in human
macular and choriocapillary tissues. Although the plasma con-
centration of CFH is in substantial molar excess over CFHR1
(Supplementary Material, Fig. S7), it remains possible that
they act jointly to suppress complement activation at different
steps in the alternative pathway.
We have measured plasma CFHR1, for the first time, in AMD
cases and controls, in addition to plasma CFH (Fig. 4). The
CNP147 deletion genotype was associated with low plasma
CFHR1, as expected (Fig. 2B), and was protective against
AMD, as reported by others (Fig. 5). However, the plasma
CFHR1 concentration was lower in AMD cases than controls
(Fig. 4) despite the fact that the frequency of the deletion is
lower and the expected level, given genotype, is higher in
cases than in controls. This was initially surprising, although a
low CFHR1 level might enhance inflammatory processes by
reduced inhibition of successive steps in the alternative
pathway. However, since we effectively excluded the possibility
of a protective association between AMD and low plasma
CFHR1 (Fig. 4), the most likely explanation is the strong associ-
ation of the CNP147 deletion with raised plasma CFH concentra-
tion which provides protection against AMD.
In the renal disease aHUS, the presence of a homozygous
CNP147 deletion is associated with increased disease risk,
whereas in AMD it is associated with reduced risk. A possible
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explanation for this discrepancy is that, in AMD, this effect is due
to LD between the CNP147 deletion andCFH variants, whereas
the deletion (and low plasma CFHR1/CFHR3) may be directly
causal in aHUS, in which the complement pathology differs in
several respects from AMD (8).
The measurement of plasma CFH and CFHR1 concentrations
in AMD cases was made after disease onset, so it is possible that
their concentrations may have been influenced by the disease
process. Mean plasma CFH concentrations were lower in the
382 SAMD cases than in 201 AMD-free controls, similar to
the findings of Reynolds et al. (42), who studied 120 advanced
AMD cases and 60 controls and found a small but statistically
significant plasma CFH reduction in AMD cases (P ¼ 0.009).
Two other studies, by Hakobyan et al. (43) (53 cases/75 controls)
and Scholl et al. (44) (112 cases/67 controls), did not find statis-
tically significant associations. However, none of these studies
measured both CFH and FHL1 in plasma and all of them were
under-powered, with only 31–42% power to detect (P, 0.05)
the observed case–control difference in plasma CFH of 0.27
standard deviations that we observed (for which our study had
84% power).
Non-synonymous CFH and CFHR1 coding variants have
functional effects on AMD risk that appear to act independently
of plasma CFH or CFHR1concentrations. For example, reduced
binding to polyanionic surfaces has been found with the
402H allele compared with 402Y (21,22). In the univariate ana-
lyses (Fig. 5), many non-coding CFH SNPs showed stronger
associations with AMD risk than the three coding (non-
synonymous) SNPs, as observed by others (23,24). The strongest
univariate SNP associations with AMD risk are likely to be with
those SNPs that are in LD with both the non-synonymous coding
variants and the proposed locus regulating plasma CFH concen-
tration (near rs6677604).
There are as yet no clinical data on the effect of raising plasma
CFH concentrations therapeutically but we would hypothesize
that raising plasma CFH concentration by 1 standard deviation
will approximately halve the incidence of AMD, based on the
results of the instrumental variable analysis, in which all the
data were examined together. However, any substantial increase
in plasma CFH would be hard to achieve in practice due to its
high plasma concentration, even if its half-life in plasma could
be extended. In individuals whose genotype encodes an appar-
ently less functionally active form of CFH (e.g. 402H homozy-
gotes), the effect of raising the concentration of the presumed
more active form (402Y) may, however, be greater than in the
general population. For therapeutic use of CFH to be feasible,
it would also be necessary to develop screening tests either for
the prediction of disease risk or for early diagnosis, and to
develop a convenient means of delivering the protein. A pro-
spective cohort study of genotype- and phenotype-based AMD
risk scores in a population of European ancestry showed a
19-fold range of predictive risk with a discriminative ability
[concordance (C) statistic ¼ 0.78] similar to that of Framingham
risk scores for coronary heart disease (5). Inclusion of non-
genetic and genetic factors in a validation sample gave a
similar C statistic of 0.809 for progression to advanced AMD
at 10 years (45). Targeting of therapy to high genetic risk indivi-
duals may, therefore, be feasible. The major source of plasma
CFH is the liver, but extra-hepatic tissues, including retinal
pigment epithelium and glomerular mesangial cells, also
contribute (7,8). Therapeutic use of CFH delivered by
2-weekly intravenous injection of fresh frozen plasma (half-life
6 days) (46) is not practicable on the necessary scale, but local
delivery of an inducible recombinant CFH to the choroid or
retinal pigment epithelium by a viral vector may be more achiev-
able (47,48). The alternative of CFH gene delivery to the liver
(49) to boost plasma concentrations raises significant risk–
benefit issues but may become feasible in the future.
MATERIALS ANDMETHODS
Subject recruitment
Subject recruitment has been described for the Croatian (26),
Dutch (Rucphen) (27), SAMD (31) and EAMD (31) samples.
The sample sizes, AMD status and contributions of each series
or cohort to the present study are summarized in Supplementary
Material, Table S1.
Plasma CFH assay
An ELISA was developed to measure plasma CFH. Blood
samples were collected in EDTA-anticoagulated tubes.
Ninety-six-well microtitre plates (Greiner Bio-One) were
coated with 50 ml of 1.2 mg/ml sheep polyclonal anti-CFH
capture antibody (Abcam), diluted in 0.1 M glycine, pH 9.5.
After 2 h of incubation at room temperature, the plates were
washed four times in 137 mM NaCl, 10 mM phosphate, 2.7 mM
KCl, pH 7.4 (PBS) and 0.05% Tween. An amount of 100 ml of
blocking solution [1% bovine serum albumin (BSA, 98% lyophi-
lized powder) in dH2O] was added and further incubation carried
out at room temperature, for at least 2 h. Doubling dilutions of
the 1.5 mg/ml CFH standard were carried out from a starting
concentration of 150 ng/ml, diluted in PBS containing 0.1%
BSA and 0.05% Tween. The CFH standard was prepared accord-
ing to the method of Sim et al. (50). Fifty microlitres of each
sample, diluted 1 in 5000, plus standard and internal control
samples were added to the plate wells, in triplicate. Samples
were incubated in plates coated with the capture antibody for
2 h at room temperature. Fifty microlitres of the 85 ng/ml
mouse monoclonal anti-CFH (MRCOX23) detection antibody
(33) which specifically detects CFH and FHL-1 (not CFHR pro-
teins) was added to each well, followed by a 3 h incubation at
room temperature. After four washes, 50 ml of the 145 ng/ml
horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG antibody (Biosource UK) was added to each well and incu-
bated for 30 min at room temperature. Plates were then washed
four times and developed after addition of 100 ml of
3,3′,5,5′-tetramethylbenzidine chromogen (Biosource UK) and
incubation for 1 h at room temperature. Enzymatic reactions
were terminated using 100 ml of 0.5 M sulphuric acid and the ab-
sorbance read at 450 nm using the SkanIt plate reader (Thermo
Electron). Internal controls were used to normalize inter-
experimental variation.
Plasma CFHR1 assay
Plasma CFHR1 concentration was determined by ELISA assay
using mouse monoclonal antibody JHD10 (17) (diluted 1 in
1000), which was immobilized on a MaxiSorp microtitre plate,
Human Molecular Genetics, 2013, Vol. 22, No. 23 4865







and non-specific binding sites were blocked with 2% BSA in
PBS, 0.05% Tween. The plates were incubated with plasma
(diluted 1 in 50, using 2% BSA in PBS, 0.05% Tween) for 1 h
at room temperature. Plates were washed and bound protein
was detected using a rabbit polyclonal anti-CFHR1 antibody
(51) (diluted 1 in 4000 using 2% BSA in PBS, 0.05% Tween).
Secondary detection was carried out using an HRP-conjugated
mouse anti-rabbit IgG antibody (diluted 1 in 4000 as before).
OPD (o-phenylenediamine dihydrochloride, Sigma, Germany)
was added and absorbance measured at 490 nm after addition
of stop solution. For each microtitre plate, CFHR1 concentra-
tions were also determined in duplicate plasma controls,
derived from one individual who is genetically identified as
homozygous CFHR3/CFHR1 sufficient (positive control) and
one individual who is homozygous CFHR3/CFHR1 deficient
(negative control). The absorbance of each plasma sample was
calculated as a fraction of the mean absorbance value of the posi-
tive controls after the background level of non-specific binding
(absorbance of the negative controls) was subtracted from all
samples. All samples were measured in duplicate, and deficiency
of the CFHR1 protein was confirmed by western blot analysis
using the rabbit polyclonal anti-CFHR1 antibody since
CFHR1, CFHR2 and CFHR5 could be separated electrophoret-
ically (Supplementary Material, Fig. S7).
The monoclonal JHD10 antibody is directed to the N-terminal
region of CFHR1 but does not cross-react with factor H, CFHR3
or CFHR4. However, it does react with CFHR2 and to a small
extent with CFHR5. This was accounted for in the ELISA by
including duplicate homozygous CFHR3/CFHR1-deficient
(CNP147) negative control samples on each plate, which mea-
sures the extent of cross-reactivity with other proteins (e.g.
CFHR2, CFHR5). The absorbance of each plasma sample was,
therefore, calculated after subtraction of this negative control
value, as a fraction of the absorbance of the positive control
value.
Genotyping
A genome-wide association scan using 317 503 SNPs (Human-
Hap300 v1.0, Illumina) was carried out in 1004 individuals from
a Croatian cross-sectional population survey in whom plasma
CFH and CFHR1 had been measured, although only 308 144
SNPs and 941 samples passed quality control procedures as
described (26). A second genome-wide association scan using
550 000 SNPs (Infinium HumanHap550-Duo BeadChip, Illu-
mina) was carried out in 874 English cases of severe AMD (geo-
graphic atrophy, choroidal neovascularization) compared with
418 disease-free controls and scored using the BeadStudio v.3
software (Illumina). Additional genotypes in the EAMD case–
controls and in an SAMD case–control series of 382 cases
and 602 disease-free controls were scored using TaqMan
probes (Applied Biosystems). Seven additional markers—
rs1061170, rs1048663, rs412852, rs1066420, rs2019727,
rs1410996 and the CFHR3/CFHR1 deletion in the Croatian data
set—and 11 markers in the Dutch (Rucphen) replication data
set—rs1061170, rs6677604, rs1329428, rs7517126, rs4086175,
rs3766404, rs1048663, rs412852, rs1066420, rs11582939,
CFHR3/CFHR1 deletion—were genotyped by TaqMan assay.
CFH rs2274700 was genotyped by direct sequencing. Quantita-
tive PCR (qPCR) of theCFHR3/CFHR1 deletion polymorphism
(18) was performed as described below. The non-synonymous
CFHR1 SNP rs388862 was genotyped by direct sequencing as
described elsewhere (38).
qPCR of CFHR3/CFHR1 deletion polymorphism
Two sets of primers and minor groove binder probes (Applied
Biosystems) were designed using the Primer Express v.2.0 soft-
ware (Applied Biosystems). Each set consisted of a pair of
primers and a 3′-fluorescent-tagged probe. One pair of primers




- fluorescent probe: AATTAGAACACAATACTTGTTGGC.
Another pair of primers and a VIC 5′-labelled probe were




- fluorescent probe: TTGCTTCTGACACAACTG.
Each qPCR was carried out in triplicate using 384-well optical
plates (Applied Biosystems). Five-microlitre reactions con-
tained 10 ng of DNA, 2.5 ml of 2× TaqMan Universal PCR
Master Mix (Applied Biosystems), 0.2 ml of each primer at
10 mM, 0.2 ml of each probe at 1 mM and 0.3 ml of water. Reac-
tions were carried out using an ABI-HT7900 instrument
(Applied Biosystems) as follows: 2 min at 508C, 10 min at
958C and 40 cycles of 15 s at 958C and 1 min at 608C. Fluores-
cence was read using the SDS software (Applied Biosystems)
and the resulting Ct values were exported and analysed as
described (52).
Statistical analyses
Statistical tests were performed using SPSS (version 19), in-
cluding Student’s t-test, and P-values are indicated in the text
and figures. Univariate and multivariate linear regression ana-
lyses were also performed using SPSS. Measurements were
expressed as means+ standard errors of the mean (SEM) or as
indicated.
Genome-wide association analysis
For genome-wide association analyses, additive effects of each
locus were modelled in a linear regression of trait values on
allele count, sex, age-by-sex and body mass index. For the Cro-
atian sample, an additional polygenic random effect was fitted
within a general linear mixed model to account for relatedness
among individuals, and GWAS was carried out using the
GenABEL R package (29,53). The effect size is reported per
copy of the minor allele. From the Croatian data set, 27 SNPs in-
cluding rs6677604 and neighbouring SNPs were carried over to a
variance components analysis using SOLAR (54) to obtain esti-
mates of additive genetic variance from the polygenic effect and
the variance explained by each SNP.
Imputation using the multi-ethnic 1000 Genomes Phase I
integrated variant set (release v3) ‘ALL’ reference panel
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(55,56) was done following guidelines from the GIANT
consortium (http://genome.sph.umich.edu/wiki/IMPUTE2:_
1000_Genomes_Imputation_Cookbook). Pre-phasing was
performed using SHAPEIT2 (57) and imputation with
IMPUTE2 (58,59).
Instrumental variable (Mendelian randomization) analysis
An instrumental variable (Mendelian randomization) analysis
was carried out (60–64) which exploits CFH and CFHR1 geno-
types as ‘instruments’ that randomize individuals to different
concentrations of plasma CFH and CFHR1. This approach,
which utilizes Bayesian models, has several advantages in the
present context over classical (frequentist) methods (60). In par-
ticular, it is straightforward to combine information from differ-
ent data sets and to allow for partially missing genotypes. The
model makes three main assumptions: (i) the effects of genotype
on AMD are not confounded (i.e. association is not due to a
common underlying cause); (ii) the effects of genotypes on
AMD are mediated only through their effects on plasma CFH
or CFHR1 (no pleiotropy); (iii) there is no developmental com-
pensation for the setting of the plasma CFH or CFHR1 level by
genotype. If these assumptions hold, we can test for causal
effects of CFH and CFHR1 by exploiting the genotypes as
‘instruments’ that perturb these biomarkers. Effect sizes on
plasma CFH and CFHR1 are represented by linear regression
coefficients, and effect sizes on AMD are represented by logistic
regression coefficients. Further details are available in Supple-
mentary Material.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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